1. Short title This Act may be cited as the Cannabidiol Research Expansion Act . 2. Definitions In this Act— (1) the term authorized medical research means medical research that is— (A) a preclinical study or clinical investigation conducted in accordance with section 505(i) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355(i) ) or otherwise permitted by the Department of Health and Human Services to determine the potential medical benefits of marihuana or cannabidiol as a drug; and (B) conducted by a covered institution of higher education, practitioner, or manufacturer that is appropriately registered under the Controlled Substances Act ( 21 U.S.C. 801 et seq.); (2) the term cannabidiol means the nonpsychoactive substance, cannabidiol, as derived from marihuana or the synthetic formulation; (3) the terms controlled substance , dispense , distribute , manufacture , marihuana , and practitioner have the meanings given such terms in section 102 of the Controlled Substances Act ( 21 U.S.C. 802 ); (4) the term covered institution of higher education means an institution of higher education (as defined in section 101 of the Higher Education Act of 1965 ( 20 U.S.C. 1001 )) that— (A) (i) has highest or higher research activity, as defined by the Carnegie Classification of Institutions of Higher Education; or (ii) is an accredited medical school or an accredited school of osteopathic medicine; and (B) is appropriately registered under the Controlled Substances Act ( 21 U.S.C. 801 et seq.); (5) the term drug has the meaning given the term in section 201(g)(1) of the Federal Food Drug and Cosmetics Act ( 21 U.S.C. 321(g)(1) ); (6) the term registered manufacturer means an individual or entity who is appropriately registered to manufacture controlled substances under the Controlled Substances Act ( 21 U.S.C. 801 et seq.), including an individual or entity appropriately registered to manufacture controlled substances as part of research